NASDAQ:OLMA Olema Pharmaceuticals (OLMA) Stock Price, News & Analysis $11.19 -0.43 (-3.70%) Closing price 04:00 PM EasternExtended Trading$10.83 -0.36 (-3.22%) As of 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Olema Pharmaceuticals Stock (NASDAQ:OLMA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Olema Pharmaceuticals alerts:Sign Up Key Stats Today's Range$11.15▼$11.5850-Day Range$9.19▼$14.0652-Week Range$4.47▼$36.26Volume655,947 shsAverage Volume1.47 million shsMarket Capitalization$977.45 millionP/E RatioN/ADividend YieldN/APrice Target$44.10Consensus RatingModerate Buy Company Overview Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. Read More Olema Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreOLMA MarketRank™: Olema Pharmaceuticals scored higher than 48% of companies evaluated by MarketBeat, and ranked 554th out of 832 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingModerate Buy Consensus RatingOlema Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 11 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialOlema Pharmaceuticals has a consensus price target of $44.10, representing about 294.1% upside from its current price of $11.19.Amount of Analyst CoverageOlema Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Olema Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Olema Pharmaceuticals are expected to decrease in the coming year, from ($2.22) to ($2.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Olema Pharmaceuticals is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Olema Pharmaceuticals is -5.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOlema Pharmaceuticals has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Olema Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.77% of the float of Olema Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverOlema Pharmaceuticals has a short interest ratio ("days to cover") of 11.29, which indicates bearish sentiment.Change versus previous monthShort interest in Olema Pharmaceuticals has recently increased by 7.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOlema Pharmaceuticals does not currently pay a dividend.Dividend GrowthOlema Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.9 / 5News Sentiment1.20 News SentimentOlema Pharmaceuticals has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Olema Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for OLMA on MarketBeat in the last 30 days. This is a decrease of -73% compared to the previous 30 days.MarketBeat Follows2 people have added Olema Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Olema Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $144,750.00 in company stock.Percentage Held by Insiders12.56% of the stock of Olema Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.78% of the stock of Olema Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Olema Pharmaceuticals' insider trading history. Receive OLMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Olema Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OLMA Stock News HeadlinesWall Street Zen Downgrades Olema Pharmaceuticals (NASDAQ:OLMA) to Strong SellJuly 25, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Olema Pharmaceuticals (OLMA)July 14, 2026 | theglobeandmail.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.July 29 at 1:00 AM | Chaikin Analytics (Ad)Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?June 30, 2026 | finance.yahoo.comHow Olema Pharmaceuticals (OLMA) Is Adding Pipeline Depth Behind Its Palazestrant Breast Cancer BetJune 17, 2026 | insidermonkey.comOlema Pharmaceuticals, Inc. (OLMA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comLifeSci Capital Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)June 8, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA), Jade Biosciences (JBIO) and Oculis Holding (OCS)June 8, 2026 | theglobeandmail.comSee More Headlines OLMA Stock Analysis - Frequently Asked Questions How have OLMA shares performed this year? Olema Pharmaceuticals' stock was trading at $25.00 at the start of the year. Since then, OLMA stock has decreased by 55.2% and is now trading at $11.19. How were Olema Pharmaceuticals' earnings last quarter? Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.52) EPS for the quarter, meeting analysts' consensus estimates of ($0.52). When did Olema Pharmaceuticals IPO? Olema Pharmaceuticals (OLMA) raised $187 million in an initial public offering (IPO) on Thursday, November 19th 2020. The company issued 11,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Jefferies, Cowen and Canaccord Genuity served as the underwriters for the IPO. Who are Olema Pharmaceuticals' major shareholders? Top institutional shareholders of Olema Pharmaceuticals include Hennion & Walsh Asset Management Inc. (0.48%). Insiders that own company stock include Bain Capital Life Sciences Inv, Bvf Partners L P/Il, Biocapital Advisors L Paradigm, Cyrus Harmon, David C Myles, Sean Bohen, Shane William Charles Kovacs, Naseem Zojwalla, Ian T Clark and Shawnte Mitchell. View institutional ownership trends. How do I buy shares of Olema Pharmaceuticals? Shares of OLMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Olema Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Olema Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), e.l.f. Beauty (ELF) and Jabil (JBL). Company Calendar Last Earnings5/12/2026Today7/29/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 OLMA's financial health is in the Red zone, according to TradeSmith. OLMA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:OLMA CIK1750284 Webwww.olema.com Phone650-243-5555FaxN/AEmployees70Year Founded2007Price Target and Rating Average Price Target for Olema Pharmaceuticals$44.10 High Price Target$62.00 Low Price Target$27.00 Potential Upside/Downside+294.1%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage14 Analysts Profitability EPS (Trailing Twelve Months)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$162.45 million Net MarginsN/A Pretax MarginN/A Return on Equity-46.00% Return on Assets-41.22% Debt Debt-to-Equity Ratio0.01 Current Ratio10.88 Quick Ratio10.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.88 per share Price / Book1.90Miscellaneous Outstanding Shares87,350,000Free Float76,376,000Market Cap$977.45 million OptionableOptionable Beta2.00 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:OLMA) was last updated on 7/29/2026 by MarketBeat.com Staff. From Our PartnersLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhere to Put $100 Before Trump's New Tech Law Rolls OutThe Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...Brownstone Research | SponsoredElon's new "super startup"Adam O'Dell - the analyst who recommended Palantir before it became the top S&P 500 performer - has identified...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Olema Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Olema Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OLMA Stock Alerts